Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer by Allegra, Carmen J. et al.
Initial Safety Report of NSABP C-08: A Randomized Phase
III Study of Modified FOLFOX6 With or Without
Bevacizumab for the Adjuvant Treatment of Patients With
Stage II or III Colon Cancer
Carmen J. Allegra, Greg Yothers, Michael J. O’Connell, Saima Sharif, Linda H. Colangelo, Samia H. Lopa,
Nicholas J. Petrelli, Richard M. Goldberg, James N. Atkins, Thomas E. Seay, Louis Fehrenbacher,
Seamus O’Reilly, Luis Chu, Catherine A. Azar, and Norman Wolmark
From the National Surgical Adjuvant
Breast and Bowel Project; Department
of Biostatistics, Graduate School of
Public Health, University of Pittsburgh;
Allegheny General Hospital, Pittsburgh,
PA; University of Florida, Gainesville,
FL; Helen F. Graham Cancer Center,
Newark, DE; University of North Caro-
lina, Chapel Hill; Southeast Cancer
Control Consortium – Community Clini-
cal Oncology Program, Goldsboro, NC;
Atlanta Cancer Care, Atlanta, GA; Kaiser
Permanente, Northern California,
Vallejo, CA; Florida Cancer Specialists,
Sarasota, FL; Kaiser Permanente, Colo-
rado, Denver, CO; and All Ireland Clini-
cal Oncology Research Group, Dublin,
Ireland.
Submitted January 9, 2009; accepted
March 24, 2009; published online
ahead of print at www.jco.org on May
4, 2009.
Supported by Public Health Service
Grants No. U10-CA-12027, U10-CA-
69651, U10-CA-37377, and U10-CA-
69974 from the National Cancer
Institute, Department of Health and
Human Services.
Presented in part at the 44th Annual
Meeting of the American Society of
Clinical Oncology, May 30-June 3,
2008, Chicago, IL.
Authors’ disclosures of potential con-
flicts of interest and author contribu-
tions are found at the end of this
article.
Clinical Trials repository link available on
JCO.org.
Corresponding author: Carmen J.
Allegra, MD, University of Florida, Divi-
sion of Hematology and Oncology,
Medical Science Bldg, N-503, 1600 SW
Archer Rd, Box 100277, Gainesville, FL
32610; e-mail: Carmen.Allegra@
medicine.ufl.edu.
The Acknowledgment is included in
the full-text version of this article,
available online at www.jco.org.
It is not included in the PDF version
(via Adobe® Reader®).
© 2009 by American Society of Clinical
Oncology
0732-183X/09/2720-3385/$20.00
DOI: 10.1200/JCO.2009.21.9220
A B S T R A C T
Purpose
The National Surgical Adjuvant Breast and Bowel Project C-08 trial was designed to investigate the
safety and effectiveness of adding bevacizumab to modified infusional fluorouracil, leucovorin, and
oxaliplatin (FOLFOX) 6 regimen for the adjuvant treatment of patients with stage II or III colon
cancer. We present safety information in advance of the planned analysis of efficacy.
Patients and Methods
Among 2,710 randomly assigned patients, demographic factors were balanced. Patients received
modified FOLFOX6 every 2 weeks  12 or modified FOLFOX6 plus bevacizumab (5 mg/kg every
2 weeks  26, experimental group).
Results
Overall rates of grade 4 or 5 toxicities were nearly identical in the FOLFOX6 and FOLFOX6 plus
bevacizumab arms (15.2% and 15.0%, respectively). Six-month mortality rates were 0.96% and
0.90% for the control and experimental groups, respectively. Grade 3 toxicities that occurred
more often in the experimental arm versus control arm included hypertension (12% v 1.8%,
respectively), wound complications (abdominal incisional hernia or infusion port dehiscence/
inflammation; 1.7% v 0.3%, respectively), pain (11.1% v 6.3%, respectively), and proteinuria
(2.7% v 0.8%, respectively). Grade 2 neuropathy was increased in the experimental arm versus
the control arm (grade 2, 33% v 29%, respectively; grade 3, 16% v 14%, respectively; and grade 4,
 1% each). In the experimental arm versus control arm, significantly less thrombocytopenia (1.4% v
3.4%, respectively) and fewer allergic reactions (3.1% v 4.7%, respectively) were observed. Advanced
age was associated with a significantly greater rate of grade 4 and 5 toxicities regardless of treatment.
Conclusion
Bevacizumab with modified FOLFOX6 is well tolerated in the surgical adjuvant setting in these
patients. No significant increase in GI perforation, hemorrhage, arterial or venous thrombotic
events, or death with the addition of bevacizumab to modified FOLFOX6 has been observed.
Follow-up for potential delayed adverse effects and efficacy is ongoing.
J Clin Oncol 27:3385-3390. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Systemic therapy for advanced colorectal cancer has
substantially improved patient outcomes, most re-
cently with the advent of targeted therapies directed
at critical growth factor pathways. Bevacizumab is a
humanized monoclonal antibody that recognizes
circulating vascular endothelial growth factor.
Hurwitz et al1 demonstrated that the addition of
bevacizumab markedly enhanced the response
rate, progression-free survival, and overall sur-
vival of patients with advanced colorectal cancer
when added to irinotecan, bolus fluorouracil
(FU), and leucovorin. Subsequent investigations
have demonstrated that the addition of bevaci-
zumab to a variety of chemotherapeutic agents
including oxaliplatin-based regimens results in
enhanced therapeutic outcomes in patients with
advanced colorectal cancer.2,3
Two large multinational randomized studies
conducted in Europe and the United States demon-
strated that the addition of oxaliplatin to the combi-
nation of FU and leucovorin resulted in significant
improvement in disease-free survival (DFS) when
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compared with FU plus leucovorin alone for the adjuvant treatment of
patients with stage II and III colon cancer.4,5 The Multicenter Interna-
tional Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adju-
vant Treatment of Colon Cancer Adjuvant Treatment of Colon
Cancer (MOSAIC) trial compared infusional FU, leucovorin, and
oxaliplatin (FOLFOX) with infusional FU plus leucovorin, whereas
the National Surgical Adjuvant Breast and Bowel Project (NSABP)
C-07 trial compared the bolus FU and leucovorin plus oxaliplatin
(FLOX) regimen with bolus FU plus leucovorin in patients with
stage II and III colon cancer. Both trials demonstrated a significant
increase in 3-year DFS for patients treated with the oxaliplatin-
containing regimens.
The primary goal of NSABP C-08 is to test the potential benefit
and safety associated with the addition of bevacizumab to the modi-
fied FOLFOX6 regimen in the adjuvant colon cancer setting. This
report summarizes the adverse events related to the use of both chem-
otherapy and bevacizumab when used in the postoperative adjuvant
setting in patients with colon cancer. The safety profile of bevaci-
zumab in combination with chemotherapy in the surgical adjuvant
setting is important to document because an increased incidence of
serious adverse events, such as perforations of the GI tract, arterial
thrombotic events, and wound complications, has been reported in
patients with advanced metastatic colorectal cancer.1,6-8
PATIENTS AND METHODS
Study Population
This study was approved by institutional review committees with assur-
ances approved by the Department of Health and Human Services and in
accordance with the Helsinki Declaration. Informed consent was required for
participation. Patient entry and characteristics are listed in Table 1.
Patients with stage II or III colon adenocarcinoma were stratified by
number of positive lymph nodes and then randomly assigned to receive either
modified FOLFOX6 for 6 months or modified FOLFOX6 for 6 months plus
bevacizumab for 12 months beginning concurrently with chemotherapy. Pa-
tients with an Eastern Cooperative Oncology Group performance status of 0 or
1 were randomly assigned within 29 to 50 days after surgical removal of the
primary tumor. Patients were excluded for any history of cerebral vascular
accident, transient ischemic attack, symptomatic peripheral vascular disease,
or a history of an arterial thrombotic episode, such as a myocardial infarction,
within 12 months before random assignment.
Regimens
Modified FOLFOX6 includes leucovorin 400 mg/m2 intravenous (IV)
on day 1, FU 400 mg/m2 IV on day 1 followed by 2,400 mg/m2 IV over 46
hours, and oxaliplatin 85 mg/m2 IV on day 1. Bevacizumab is administered on
the experimental arm at a dose of 5 mg/kg IV on day 1. All therapy is admin-
istered every 2 weeks for 12 doses (6 months) or, for bevacizumab, 26 doses
(1 year).
Adverse Event Reporting
Adverse events were reported using the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 3.0.9 Routine reporting
was required for all events  grade 3 (except all neurology events, which were
reported for all events  grade 2) every 6 weeks during active treatment and
every 3 months for 1 year after therapy.
Dose Modifications
Oxaliplatin and FU were reduced for grade 3 and 4 adverse events except
for diarrhea and stomatitis, wherein only FU was reduced for less than grade 4
toxicity, or neurologic toxicities, wherein only oxaliplatin was modified for
grades 3 and 2, provided the toxicity exceeded 7 days in duration.
There were no dose modifications for bevacizumab, but the drug was
held for grade 1 noninfectious wound complications, grade 2 proteinuria or
thrombosis, or any clinically significant and related grade 3 toxicities. Bevaci-
zumab was discontinued for any grade of GI perforation or reversible posterior
leukoencephalopathy syndrome, grade 2 or greater ischemic events or nonin-
fectious wound complications, grade 3 hemorrhage, or any associated grade
4 toxicities.
Statistical Considerations
Rates of toxicity were computed by dividing the number of patients
reporting the relevant toxicity by the number of patients reported to have been
assessed for toxicity. Rates and the distributions of categoric variables were
compared using 2 or Fisher’s exact tests. Continuous variables were presented
as medians and compared between groups using the Wilcoxon test. The
Kaplan-Meier method was used to present the proportion of patients exceed-
ing a given duration of therapy.
Analyses related to compliance with protocol therapy and the reason for
discontinuation of protocol therapy were restricted to the cohort of patients
without an event for the primary efficacy end point of DFS (time to recurrence,
second primary cancer, or death). This was done so that no one could attribute
any differences found to efficacy of the study drug.
RESULTS
During the 2-year period between September 2004 and October 2006,
2,710 patients from 292 participating centers were accrued to the
study. Patient demographics are well balanced by treatment arm (Ta-
ble 1). Each arm had just over 1,350 patients. The mean time on study
as of March 31, 2008, was 28.5 months. Slightly more than half of the
patients were less than 60 years of age, and there was an equal sex
distribution. Stage II patients constituted approximately 25%, with
the balance being node-positive patients.
In the cohort of patients without a DFS event, 73% v 78% and
80% v 85% were able to receive at least 10 of 12 planned doses of
Table 1. Patient Entry, Demographics, and Clinical Characteristics
Patient Demographics and Clinical
Characteristics mFOLFOX6 mFOLFOX6  Bev
Patient population, No. of patients
Randomly assigned 1,356 1,354
Ineligible 18 14
With follow-up 1,338 1,332
Mean time on study, months 28.5 28.5
Age, years, % of patients
 60 58.3 58.1
 60 41.7 41.9
Sex, % of patients
Male 49.8 49.8
Female 50.2 50.2
Race, % of patients
White 87.6 87.0
Black 7.5 8.6
Other 3.8 3.1
Multiracial 0.1 0.1
Unknown 1.0 1.2
Stage, % of patients
II (node negative) 24.7 25.0
III (1-3 positive nodes) 45.7 45.4
III (4 positive nodes) 29.6 29.6
Abbreviations: mFOLFOX6, modified infusional fluorouracil, leucovorin, and
oxaliplatin; Bev, bevacizumab.
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oxaliplatin and FU in the control versus experimental arms, respec-
tively (P  .01, each drug). A significantly greater percentage of
patients were able to receive at least 1,000 mg/m2 of the protocol-
specified cumulative oxaliplatin dose of 1,020 mg/m2 on the bevaci-
zumab arm versus the control arm (34% v 27%, respectively; P  .01).
The median dose of oxaliplatin delivered on the chemotherapy-alone
arm was 850 mg/m2 compared with 880 mg/m2 delivered on the
bevacizumab arm (P  .01). The oxaliplatin median dose-intensity
was also slightly higher on the bevacizumab arm compared with the
chemotherapy-alone arm (83.2 v 81.1 mg/m2/2-week cycle), although
this did not reach the level of statistical significance (P  .13). The FU
doses followed similar trends, with patients on the chemotherapy-
alone arm receiving a median dose of 29,540 mg/m2 and patients on
the bevacizumab arm receiving 30,800 mg/m2 (P  .01). The median
dose-intensity of FU was similar on the control and experimental
arms (2,688 v 2,720 mg/m2/2-week cycle, respectively; P  .57). Sixty-
one percent of patients were able to receive at least 21 of 26 planned
doses of bevacizumab. The median duration of bevacizumab therapy
was 11.5 months.
Two thirds of patients who discontinued bevacizumab in the
cohort of patients without a DFS event did so because of an adverse
event, whereas 24% withdrew at the patient’s request. These percent-
ages were closely mirrored in the reasons for discontinuation of chem-
otherapy. As shown in Figure 1, during the first 6 months of therapy,
the decrement in patients receiving bevacizumab was precisely paral-
leled by the fall-off in patients receiving therapy with FU on the control
arm, whereas the fall-off trails that of FU on the experimental arm.
These data suggest that discontinuation of bevacizumab occurred
primarily in conjunction with chemotherapy-associated adverse
events and was the first agent to be discontinued in the experimental
arm because of adverse events that were not clearly attributable to a
particular agent. During the 6 months after completion of chemother-
apy, discontinuation of bevacizumab occurred at a slower rate.
Death from any cause within 6 months of random assignment
among treated patients occurred in 0.96% and 0.90% of individuals
(P  1.0) in the control and bevacizumab arms, respectively. At 18
months after random assignment, 1.33% and 1.35% of treated
patients died in the control and bevacizumab arms, respectively
(P  1.0).
The overall rates of grade 4 and 5 toxicity were 15.2% and 15.0%
in the chemotherapy-alone and chemotherapy plus bevacizumab
arms, respectively (P  .91). The overall rate of grade 3 or higher
toxicities was 70% in the chemotherapy-alone arm and 77% in the
chemotherapy plus bevacizumab arm (P  .01).
Specific grade 3 or higher toxicities associated with chemothera-
py or with bevacizumab in the advanced-disease setting are listed in
Table 2. None of the differences in these toxicities is significant be-
tween the control and bevacizumab arms. However, several toxicities
were significantly different in patients receiving bevacizumab (Table
3). These included hypertension, pain, proteinuria, sensory neuropa-
thy, and wound complications, which occurred in less than 2% of
patients treated with bevacizumab. Of the 23 patients with wound
complications on the bevacizumab arm (all grade 3), all but one
required surgical intervention, and half required bevacizumab discon-
tinuation. Fourteen of these patients had symptomatic abdominal
Table 2. Therapy-Associated Grade 3 or Greater Adverse Events Not
Significantly Increased in NSABP C-08
Adverse Event
% of Patients
mFOLFOX6
(n  1,321)
mFOLFOX6  Bev
(n  1,326)
Venous thrombosis 4.6 6.3
Neutropenia 32.6 29.4
Febrile neutropenia 1.7 1.2
Fatigue 7.2 9.0
Diarrhea 9.7 11.1
Dehydration 4.0 4.8
Cardiac ischemia 0.8 1.5
CNS ischemia 0.4 0.4
Peripheral arterial ischemia 0.2 0.0
GI perforation 0.2 0.3
Any hemorrhage 1.9 1.9
Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel Project;
mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxaliplatin;
Bev, bevacizumab.
Not statistically significantly different (P  .05) unless noted.
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Fig 1. Duration of fluorouracil (FU) and bevacizumab (Bev) therapy for patients
randomly assigned to either the control arm (green line  FU) or the experimental
arm (blue line  FU, and red line  Bev). In each case, the percentage of patients
remaining on therapy is plotted as a function of time on therapy. Patients
reaching a disease-free survival (DFS) event were excluded from this analysis.
mFF6, modified infusional fluorouracil, leucovorin, and oxaliplatin.
Table 3. Grade 3 or Greater Toxicities Significantly Different by Treatment
in NSABP C-08
Adverse Event
% of Patients
P
mFOLFOX6
(n  1,321)
mFOLFOX6  Bev
(n  1,326)
Sensory neuropathy 14.4 16.7 .10
Grade  2 43.7 48.9  .011
Hypertension 1.8 12.0  .011
Proteinuria 0.8 2.7  .011
Wound complications 0.3 1.7  .011
Pain (joint, muscle, bone,
chest/thorax, abdomen,
head/headache, or
rectum) 6.3 11.1  .011
Thrombocytopenia 3.4 1.4  .012
Allergic reaction 4.7 3.1 .032
Abbreviations: NSABP, National Surgical Adjuvant Breast and Bowel
Project; mFOLFOX6, modified infusional fluorouracil, leucovorin, and oxali-
platin; Bev, bevacizumab; 1, increased with bevacizumab; 2, decreased
with bevacizumab.
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incisional hernias, and one patient had an abdominal wound dehis-
cence associated with an abscess. The median time to occurrence of
these events was 5 months. The other nine patients developed infusion
port dehiscence and/or inflammation. The median time to occurrence
in these patients was 2 months. There was no difference in the time
from surgical procedure to the initiation of therapy (median, 46 days)
between patients who developed a wound complication versus those
who did not (P  .88). Although grade 3 sensory neuropathy was not
different between the arms, the overall rate of grade 2 and higher
sensory neuropathy was significantly increased in the bevacizumab
arm (P .01). This difference may be the result of a greater cumulative
dose of oxaliplatin received by patients randomly assigned to the
bevacizumab arm. Pain, which was also significantly increased in the
bevacizumab arm, was primarily in the form of chest, joint, or muscle
pain. Each of these occurred at a rate of approximately two-fold
greater in the bevacizumab arm. Of interest, there was less throm-
bocytopenia and fewer allergic reactions in patients receiv-
ing bevacizumab.
To assess toxicities that occurred during the 6 months of therapy
with bevacizumab alone, we tabulated only toxicities that occurred
during the 1 year after chemotherapy completion (Table 4). Those
found to occur at a significantly higher level included wound compli-
cations consisting almost entirely of symptomatic abdominal wall
incisional hernias, hypertension, sensory neuropathy, depression, diz-
ziness, proteinuria, and pain.
We also examined the maximum grade of adverse event as a
function of decade of patient age for the overall study population (Fig
2). We found that the distribution of maximum grade of adverse event
differed significantly among the six age decades examined (P  .001).
Grade 4 and 5 toxicities seemed to increase in both arms for patients
older than age 60 years and in particular for patients older than age 70,
who constituted 15.8% and 14.5% of patients on the control and
experimental arms, respectively. There were large differences in grade
4 neutropenia by age (6%  70 years v 13%  70 years, P  .001).
Patients older than age 70 had a significantly higher rate of fatal
adverse events compared with the younger population (3.0% v 0.8%,
respectively; P  .001). In comparing all toxicities by age, the overall
rate of grade 3 toxicities was greater in patients older than 70 years
versus younger patients (81% v 73%, respectively; P  .001); specifi-
cally, there was significantly more grade 3 neutropenia (44.2% v
28.8%, respectively; P  .001), thrombocytopenia (4.8% v 2.0%, re-
spectively; P  .002), fatigue (15.2% v 6.9%, respectively; P  .001),
diarrhea (16.4% v 9.5%, respectively; P  .001), dehydration (10.9% v
3.4%, respectively; P  .001), and febrile neutropenia (3.5% v 1.1%,
respectively; P  .001). Overall, the effects of age (70 years) and
treatment on the rate of grade 4 adverse events seem to be indepen-
dent (Breslow-Day test for homogeneity of odds ratios, P  .49).
Patients age  60 years had a significantly lower dose-intensity com-
pared with patients less than 60 years of age for both oxaliplatin and
FU (P  .0001).
DISCUSSION
The overall safety of adding bevacizumab to modified FOLFOX6 in
the colon cancer adjuvant setting is acceptable in the selected popula-
tion of patients eligible for NSABP C-08. The C-08 population had an
excellent performance status, with no prior history of a cerebral vas-
cular accident or peripheral arterial event, and had at least a 12-month
interval before random assignment for any myocardial infarction and
no exposure to bevacizumab before the 29th postoperative day.
The cumulative dose and dose-intensity of modified FOLFOX6
were not decreased by the addition of bevacizumab, yet the overall
rates of mortality from any cause within 6 months were nearly identi-
cal on both arms. The rate of less than 1% for 6-month mortality is
similar to other colon cancer adjuvant trials conducted in the United
States. The 6-month mortality reported for NSABP C-07,5 which
randomly assigned patients to either weekly FU plus leucovorin or the
same chemotherapy with the addition of oxaliplatin, was 0.9% and
1.0% for each arm, respectively. Similarly, past trials using primarily
FU-based regimens reported 6-month mortality rates of 0.8%
to 1.2%.10,11
Overall, we did not observe any change in the rate of toxicities
generally attributable to the chemotherapeutic agents used; however,
we did observe an increase in the rate of grade 2 or higher neuropathy
in patients randomly assigned to the bevacizumab arm. Our observed
6% absolute increase in neuropathy may be attributable to the increase
Table 4. Grade 3 or Greater Toxicities Seen Significantly More Frequently
With Bevacizumab After Chemotherapy
Adverse Event
% of Patients
P
mFOLFOX6
(n  1,321)
mFOLFOX6  Bev
(n  1,326)
Wound
complications 0.3 1.1 .01
Hypertension 0.7 5.9  .01
Sensory neuropathy
(grade  2) 26.1 32.4  .01
Any pain 2.1 4.8  .01
Proteinuria 0.2 1.6  .01
Depression 1.3 2.9  .01
Dizziness 0.7 1.6 .04
Abbreviations: mFOLFOX6, modified infusional fluorouracil, leucovorin, and
oxaliplatin; Bev, bevacizumab.
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Fig 2. Maximum grade of toxicities by age decade is illustrated for both arms
combined because the rates of AEs were similar in both arms. Patients are
separated into age decades of less than 40 (light blue bars), 40 to 49 (dark red
bars), 50 to 59 (gray bars), 60 to 69 (bright blue bars), 70 to 79 (gold bars), and
 80 years old (dark blue bars).
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in cumulative dose of oxaliplatin received by patients randomly as-
signed to the bevacizumab arm because 7% more patients received at
least 1,000 mg/m2 of oxaliplatin on this arm compared with the con-
trol arm. One hypothesis for the greater cumulative dose of chemo-
therapy in the bevacizumab arm is that when toxicities that were not
clearly attributable to a specific agent occurred, physicians may have
elected to first discontinue bevacizumab rather than dose modify
chemotherapy. Such an option was not available in the control arm;
thus, physicians were forced to first dose modify the chemotherapy,
with a resultant decrease in cumulative dose relative to the experimen-
tal arm. Evidence for this hypothesis is illustrated in Figure 1, wherein
discontinuation of bevacizumab exactly parallels the discontinuation
of FU in the control arm but lags behind FU discontinuation in the
experimental arm. This suggests that nonspecific toxicities requiring
dose modifications occurred at the same rate in both arms, but bev-
acizumab was favored as a first option for discontinuation rather than
chemotherapy in the experimental arm, thus preserving chemothera-
py dose-intensity.
Several toxicities generally associated with bevacizumab in the
advanced-disease setting were not found to be increased. Specifically,
cardiac, CNS, and peripheral arterial events were not increased in the
bevacizumab-treated patients. Similarly, we did not observe an in-
crease in the rate of GI perforations despite all patients having had a
prior major surgical intervention. However, there was an approxi-
mately five-fold increase in the rate of wound complications (all grade
3) in patients treated with bevacizumab versus chemotherapy alone
(1.7% v 0.3%, respectively). The lack of an increased incidence of GI
perforations and the relatively low incidence of manageable wound
complications may be attributable to an adequate interval between
surgical intervention and the initiation of anti–vascular endothelial
growth factor therapy.
As anticipated, both hypertension and proteinuria occurred at a
significantly higher rate in the bevacizumab arm versus control arm
(12% v 2.7%, respectively). There were no occurrences of frank ne-
phrotic syndrome, and grade 4 hypertension occurred in only five
patients. Pain (joint, muscle, and noncardiac chest pain) of unclear
pathogenesis was also found to be approximately two-fold higher in
the bevacizumab arm. Although this toxicity has been previously
reported with bevacizumab,1 it has not been found to be significantly
increased, presumably because of the small number of patients
treated on the advanced-disease studies relative to NSABP C-08. Of
interest, we noted a decrease in the occurrence of allergic reactions
and thrombocytopenia.
One feature of the NSABP C-08 trial is the exclusive use of
bevacizumab for 6 months after completion of chemotherapy.
Wound complications, hypertension, proteinuria, and pain all con-
tinued to be observed during this 6-month period of bevacizumab
alone, although all occurred at a substantially lower rate compared
with during the first 6 months that included chemotherapy. Dizzi-
ness and depression were not increased during the first 6 months
but were increased (borderline significance for dizziness) during
the bevacizumab-alone period. Part of the explanation for this obser-
vation is that the follow-up periods were more frequent for the bev-
acizumab group (every 6 weeks) compared with the control group,
which had completed active therapy (every 3 months). Although
sensory neuropathy continued to be observed more frequently in the
bevacizumab arm, this was presumably a result of a higher prevalence
of this toxicity at the start of the 6-month bevacizumab-alone period
relative to the control arm. The rate of reversal of this toxicity during
this period was similar in both arms (approximately 35%).
Finally, we found that with age greater than 60 years, there was a
clear increase in grade 4 (primarily neutropenia) and 5 adverse events
independent of treatment. The association of increasing age with
excess toxicity has been reported with FOLFOX chemotherapy.12
Consistent with our observations, these authors identified a significant
increase in hematologic toxicity (grade 2) in patients at least 70 years
of age. Although 60-day mortality in the pooled analysis report was
found to be higher in the elderly (2.3% v 1.1% in younger patients),
this difference was not statistically significant.12 Patients older than age
70 who participated in NSABP C-08 clearly had a significantly higher
rate of fatal adverse events compared with the younger population
(3.0% v 0.8%, respectively; P  .001). Given these observations in the
relatively small patient cohort older than age 70 accrued to NSABP
C-08 (approximately 15%), caution should be exercised in consider-
ing the use of bevacizumab in this population.
Although the use of bevacizumab in combination with the mod-
ified FOLFOX6 chemotherapeutic regimen is associated with an ac-
ceptable toxicity profile in the specific patient population eligible for
NSABP C-08, ongoing efforts continue to investigate any potential
long-term toxicities associated with the use of bevacizumab. The use
of bevacizumab in the adjuvant colon setting cannot be recommended
at the present time. Further follow-up will be required to determine
whether the addition of bevacizumab to the modified FOLFOX6
regimen will result in a significant improvement in DFS.
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